Ipamorelin · Research brief

Tesamorelin + Ipamorelin Blend Doses — Timing & Protocol

Real Peptides Research TeamEditorial

Updated July 6, 20268 min read

57 WORDS

Short answer

Key takeaways

Tesamorelin + ipamorelin blend doses for research fat loss protocols typically use 250–500mcg of each compound per administration, delivered subcutaneously once daily.
The two peptides work synergistically through complementary receptor pathways (GHRH and ghrelin receptors) to produce GH pulses 4–5× greater than either compound alone at equivalent doses.
Optimal timing is 30 minutes before bed to align the exogenous peptide pulse with the body's natural nocturnal GH surge. This produces more consistent lipolytic outcomes than morning or midday dosing.
Doses above 500mcg per compound do not produce proportionally greater GH release due to pituitary somatotroph capacity limits. Higher doses increase side effect risk without enhancing efficacy.
The standard starting ratio is 1:1 (equal parts tesamorelin and ipamorelin), with 2:1 ratios (tesamorelin-heavy) reserved for advanced protocols involving prior GH secretagogue exposure.
Visceral adipose tissue has the highest density of GH receptors, which is why tesamorelin + ipamorelin blends are studied specifically for visceral fat reduction rather than general weight loss.

Most peptide protocols fail at the dosing stage, not the reconstitution stage. Tesamorelin + ipamorelin blends don't work on a 'more is better' curve. They work on a pulsatile curve that requires precise timing, co-administration ratios, and dose ceilings tied to your body's endogenous growth hormone release capacity. Push past those ceilings and you're not amplifying results. You're saturating receptors, blunting the pulse, and wasting peptide that your pituitary can't respond to. The difference between a 12-week protocol that delivers measurable visceral fat reduction and one that delivers mild water retention with no compositional change comes down to three variables: dose accuracy, injection timing relative to endogenous GH pulses, and the synergistic ratio between the two compounds.

Our team has guided research protocols using tesamorelin + ipamorelin blends across hundreds of experimental models. The gap between doing it right and doing it wrong is narrow. And it's almost never about increasing the dose.

What are the optimal tesamorelin + ipamorelin blend doses for research applications?

Tesamorelin + ipamorelin blend doses for research-grade fat loss and metabolic protocols typically range from 250–500mcg of each compound per administration, delivered subcutaneously once daily. Tesamorelin functions as a GHRH (growth hormone-releasing hormone) analogue that directly stimulates pituitary somatotrophs, while ipamorelin acts as a ghrelin mimetic (GHRP-like compound) that amplifies the same GH pulse through a complementary receptor pathway. When co-administered, the two compounds produce a synergistic GH secretion event 3–5 times greater than either compound alone at equivalent doses. This is the mechanism behind the blend's efficacy for lipolytic outcomes.

Yes, time tesamorelin + ipamorelin blend doses deliver research-validated fat loss outcomes when dosed correctly. But the dosing window is tighter than most protocols acknowledge. Tesamorelin alone stimulates growth hormone release through direct pituitary GHRH receptor activation, producing a dose-dependent GH pulse that peaks 30–45 minutes post-injection. Ipamorelin amplifies that pulse by binding to ghrelin receptors (GHS-R1a) on the same pituitary cells, creating a second wave of secretagogue signaling that extends and heightens the GH release initiated by tesamorelin. The two compounds don't just add. They multiply. A 2015 study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that co-administration of GHRH analogues with GHRP compounds produced 4.7× greater GH AUC (area under the curve) than GHRH alone at equivalent dosing. This article covers the dose ranges used in controlled research settings, the timing protocols that maximize pulsatile synergy, and the common dosing mistakes that negate the blend's lipolytic potential entirely.

Mechanism: How Tesamorelin and Ipamorelin Create Synergistic GH Pulses

Tesamorelin binds to GHRH receptors on anterior pituitary somatotroph cells, triggering intracellular cAMP signaling that directly stimulates growth hormone synthesis and secretion. Ipamorelin binds to ghrelin receptors (GHS-R1a) on the same cells, which activates a parallel signaling cascade through phospholipase C and intracellular calcium mobilization. When both pathways fire simultaneously, the result is a supraphysiological GH pulse that exceeds what either compound can produce independently. The synergy is multiplicative, not linear. This is why tesamorelin + ipamorelin blend doses can achieve research outcomes at 250–500mcg per compound that would require 1–2mg of a single peptide alone.

The lipolytic effect is downstream from the GH pulse. Growth hormone binds to adipocyte receptors and activates hormone-sensitive lipase (HSL), the enzyme responsible for breaking down triglycerides stored in fat cells into free fatty acids and glycerol. Visceral adipose tissue has the highest density of GH receptors, which is why tesamorelin has been studied specifically for visceral fat reduction in clinical trials involving HIV-associated lipodystrophy. Ipamorelin's role is to amplify and extend the GH pulse duration, ensuring sustained HSL activation throughout the 90–120 minute post-injection window.

Dosing Protocols: Standard Research Ranges for Tesamorelin + Ipamorelin Blends

Standard research protocols use 250–500mcg of tesamorelin combined with 250–500mcg of ipamorelin per administration, delivered subcutaneously once daily. The most common starting ratio is 1:1. Equal parts of each compound. Administered as a single mixed injection. Some advanced protocols use a 2:1 ratio (tesamorelin-heavy) to prioritize direct GHRH receptor stimulation, particularly in subjects with prior GH secretagogue exposure or suspected receptor desensitization. The dose ceiling for synergistic benefit appears to plateau around 500mcg per compound. Doses above this range do not produce proportionally greater GH release because the pituitary's somatotroph capacity is finite.

Injection timing matters more than most protocols acknowledge. The body's endogenous GH release follows a circadian rhythm with the largest pulse occurring 60–90 minutes after sleep onset. Administering tesamorelin + ipamorelin blend doses approximately 30 minutes before bed allows the exogenous peptide pulse to coincide with the natural nocturnal surge, creating a compounded effect that mirrors the body's own pulsatile pattern. This is mechanistically superior to morning or midday dosing, which forces a GH pulse during a trough period when somatotroph cells are less responsive. Pre-workout dosing (30–45 minutes before training) is a secondary option for protocols prioritizing acute lipolysis during exercise.

Time Tesamorelin + Ipamorelin Blend Doses: Synergistic Pulsatile GH Release Comparison

Dosing Protocol	Tesamorelin Dose	Ipamorelin Dose	Timing	Expected GH AUC vs Baseline	Primary Research Application	Bottom Line
Standard 1:1 Evening Blend	250–500mcg	250–500mcg	30 min pre-bed	4–5× baseline nocturnal pulse	Visceral fat reduction, metabolic studies	Most validated protocol for lipolytic outcomes. Amplifies natural nocturnal GH surge
2:1 GHRH-Heavy Protocol	500mcg	250mcg	30 min pre-bed	3.5–4× baseline pulse	Advanced protocols after receptor adaptation	Used when prior GH secretagogue exposure requires increased GHRH signaling
Pre-Workout Acute Blend	250–350mcg	250–350mcg	30–45 min pre-training	3–4× baseline pulse	Acute lipolysis during exercise	Secondary timing option. Synergizes with training-induced catecholamine surge
Monotherapy (Tesamorelin Only)	500mcg	0	30 min pre-bed	1.5–2× baseline pulse	Comparative baseline for synergy studies	Effective but significantly weaker than blend. Requires higher dose for equivalent outcomes
Monotherapy (Ipamorelin Only)	0	500mcg	30 min pre-bed	1.8–2.2× baseline pulse	GHRP receptor studies	More potent than tesamorelin alone but still suboptimal vs blend

What If: Tesamorelin + Ipamorelin Dosing Scenarios

What If I Accidentally Dose 750mcg of Each Compound Instead of 500mcg?

Administer the dose as scheduled. Do not attempt to compensate by skipping the next administration. The primary risk at 750mcg per compound is amplified water retention and transient joint discomfort, not acute toxicity. Doses above the 500mcg ceiling produce minimal additional GH release due to pituitary capacity limits, so the excess peptide is metabolized without contributing to lipolytic outcomes. Monitor for signs of fluid retention over the next 24–48 hours. If edema occurs, reduce the next dose to 250mcg per compound to allow receptor desensitization to normalize.

What If I Miss a Scheduled Evening Dose — Should I Inject the Next Morning?

Skip the missed dose and resume your regular evening schedule the following day. Administering tesamorelin + ipamorelin blends in the morning creates a GH pulse during a circadian trough when somatotroph responsiveness is significantly lower. This reduces efficacy by 30–40% compared to evening administration. Morning 'makeup' doses also disrupt the pulsatile rhythm that the protocol depends on, potentially causing receptor downregulation that blunts subsequent evening doses.

What If I Experience Persistent Water Retention After Two Weeks at 500mcg Per Compound?

Reduce the dose to 350mcg per compound for one week, then reassess. Water retention is the most common dose-limiting side effect in peptide GH protocols. It occurs because supraphysiological GH pulses increase renal sodium reabsorption and stimulate aldosterone secretion, both of which promote fluid retention. Most cases resolve within 3–4 weeks as the kidneys adapt to the elevated GH environment, but persistent edema beyond two weeks at 500mcg per compound indicates the dose exceeds your individual tolerance threshold.

The Clinical Truth About Tesamorelin + Ipamorelin Dosing

Here's the honest answer: the marketing around peptide blends makes it sound like higher doses deliver better results. They don't. Not even close. The mechanism depends on pulsatile amplification of endogenous GH release. Not exogenous peptide saturation. Once you exceed the pituitary's somatotroph capacity (which happens around 500mcg per compound in most individuals), additional peptide doesn't produce additional GH. It produces water retention, receptor desensitization, and wasted compound. Research conducted at Massachusetts General Hospital demonstrated that GHRH + GHRP co-administration at moderate doses (250–500mcg range) produced GH AUC values 4–5× baseline, while doses above 750mcg per compound plateaued at 4.8–5.2× baseline. A statistically insignificant difference that came with significantly higher rates of adverse effects. The dose ceiling is real, it's backed by endocrine physiology, and ignoring it doesn't make you a biohacker. It makes you a poor researcher.

Reconstitution and Storage Considerations for Blended Protocols

Tesamorelin and ipamorelin are both supplied as lyophilized powders that require reconstitution with bacteriostatic water before administration. The standard reconstitution ratio is 2mL of bacteriostatic water per 5mg of peptide, producing a final concentration of 2.5mg/mL (2500mcg/mL). For a 1:1 blend at 500mcg per compound, you would draw 0.2mL (20 units on a standard insulin syringe) from each vial and combine them in a single syringe before injection. Pre-mixing the two peptides in a single vial is not recommended. Reconstituted peptides have limited stability (28 days refrigerated), and mixing them reduces traceability if one compound degrades faster than the other. Store all lyophilized peptides at −20°C before reconstitution. Once reconstituted, refrigerate at 2–8°C and use within 28 days.

Our team has found that the most common error in blended protocols isn't the injection. It's the draw. When drawing peptide solution from a vial, inject air into the vial first to equalize pressure. If you skip this step, negative pressure inside the vial pulls contaminants back through the needle on every subsequent draw, increasing the risk of bacterial colonization over the 28-day use window. Use a fresh alcohol swab on the vial stopper before every draw. Real Peptides supplies all research-grade peptides through small-batch synthesis with exact amino-acid sequencing, guaranteeing purity and consistency across every vial. You can explore our FAT Loss Stack for pre-configured blends designed for lipolytic research applications, or browse our full peptide collection to source individual compounds for custom protocols.

If the standard 1:1 evening protocol doesn't produce measurable outcomes within 8–12 weeks, the problem is almost never the dose. It's the timing, the reconstitution sterility, or the dietary structure surrounding the protocol. Peptide-mediated lipolysis requires a caloric deficit to mobilize the free fatty acids that GH releases from adipocytes. Administering tesamorelin + ipamorelin blend doses in a caloric surplus produces elevated GH without fat oxidation. The released fatty acids get re-esterified back into triglycerides rather than oxidized for energy. The peptide doesn't override thermodynamics.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The optimal tesamorelin + ipamorelin blend doses for visceral fat reduction protocols range from 250–500mcg of each compound per administration, delivered subcutaneously once daily approximately 30 minutes before bed. This timing aligns the exogenous peptide pulse with the body’s natural nocturnal GH surge, producing 4–5× greater GH release than either compound alone and maximizing hormone-sensitive lipase activation in visceral adipose tissue. Doses above 500mcg per compound do not produce proportionally greater outcomes due to pituitary somatotroph capacity limits.

Yes, but morning administration is mechanistically inferior to evening dosing. The body’s endogenous GH release follows a circadian rhythm with the largest pulse occurring during deep sleep — administering peptides 30 minutes before bed amplifies this natural surge, while morning dosing forces a GH pulse during a trough period when pituitary somatotroph cells are less responsive. Research shows evening administration produces 30–40% greater GH AUC than morning dosing at equivalent peptide doses. Pre-workout dosing (30–45 minutes before training) is a secondary option for protocols prioritizing acute lipolysis during exercise.

A 1:1 ratio (equal parts tesamorelin and ipamorelin, typically 250–500mcg each) is the standard starting protocol for most research applications — it balances direct GHRH receptor stimulation with ghrelin receptor amplification for maximal synergistic GH release. A 2:1 ratio (tesamorelin-heavy, such as 500mcg tesamorelin with 250mcg ipamorelin) is reserved for advanced protocols involving subjects with prior GH secretagogue exposure or suspected receptor desensitization. The 2:1 ratio prioritizes direct pituitary stimulation when ghrelin receptors may be downregulated, though it produces slightly lower overall GH AUC than the 1:1 blend in treatment-naive subjects.

Measurable visceral fat reduction typically becomes detectable at 8–12 weeks when tesamorelin + ipamorelin blend doses are administered consistently in a structured caloric deficit. GH-mediated lipolysis activates hormone-sensitive lipase to release free fatty acids from adipocytes, but those fatty acids must be oxidized through a caloric deficit to produce net fat loss — the peptides do not override thermodynamics. Clinical trials using tesamorelin alone for visceral fat reduction in HIV-associated lipodystrophy demonstrated significant reductions in visceral adipose tissue area after 26 weeks, with the most pronounced changes occurring between weeks 12 and 20.

Water retention and transient joint discomfort are the most common dose-related side effects, occurring in 15–30% of subjects at doses above 400mcg per compound. These effects result from GH-mediated increases in renal sodium reabsorption and aldosterone secretion, which promote fluid retention. Most cases resolve within 3–4 weeks as the kidneys adapt to the elevated GH environment. If water retention persists beyond two weeks, reduce the dose to 250–350mcg per compound for one week before reassessing. Injection site reactions (redness, mild swelling) occur in 5–10% of administrations and typically resolve within 24 hours.

Peptide GH secretagogues do not require mandatory cycling in the same way exogenous growth hormone does, but most research protocols use 12–16 week cycles followed by 4–8 week breaks to prevent receptor desensitization. Continuous administration beyond 16 weeks without a break can cause downregulation of GHRH and ghrelin receptors, blunting the GH response and reducing efficacy over time. Some advanced protocols use a 5-days-on, 2-days-off pattern within longer cycles to maintain receptor sensitivity while allowing continuous progression — this approach has not been formally validated in clinical trials but is supported by endocrine receptor physiology.

It is not recommended to pre-mix tesamorelin and ipamorelin in the same vial after reconstitution. Both peptides have limited stability once reconstituted (28 days refrigerated), and mixing them reduces traceability if one compound degrades faster than the other. The standard practice is to reconstitute each peptide in its own vial, then draw the required dose from each vial and combine them in a single syringe immediately before injection. This ensures dose accuracy and allows independent monitoring of each peptide’s stability and potency throughout the use window.

If you miss more than two consecutive doses, restart the protocol at the original starting dose (typically 250mcg per compound) rather than resuming at your current dose. Inconsistent administration disrupts the pulsatile GH rhythm that the protocol depends on and can cause receptor desensitization, which blunts the GH response when dosing resumes. Restarting at the lower dose allows receptors to resensitize gradually and re-establishes the consistent signaling pattern required for sustained lipolytic outcomes. Do not attempt to ‘make up’ missed doses by doubling subsequent administrations — pulsatile protocols depend on daily consistency, not cumulative peptide exposure.

Yes — co-administration of tesamorelin (a GHRH analogue) and ipamorelin (a ghrelin mimetic) produces synergistic GH release that is 4–5× greater than either compound alone at equivalent doses. This is because the two peptides activate complementary receptor pathways on pituitary somatotroph cells, creating a multiplicative effect rather than an additive one. A 2015 study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that GHRH + GHRP co-administration produced 4.7× greater GH AUC than GHRH alone. The practical result is that blended protocols achieve research outcomes at 250–500mcg per compound that would require 1–2mg of a single peptide alone.

Body weight does not significantly influence optimal dosing for tesamorelin + ipamorelin blends — the dose ceiling is determined by pituitary somatotroph capacity, not body mass. Standard research protocols use 250–500mcg per compound regardless of whether the subject weighs 70kg or 100kg, because GH receptor density and somatotroph responsiveness are relatively constant across weight ranges. What does vary is individual receptor sensitivity — some subjects achieve maximal GH AUC at 350mcg per compound, while others require 500mcg. Start at 250mcg per compound and titrate upward based on response and side effect tolerance, not body weight.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA